Inside the bioreactor dilemma: stainless steel vs single‑use for new biologics plants

When a biopharma company draws up a greenfield facility, one decision now shapes the entire budget, schedule, and operating model: stainless‑steel (SS) bioreactors versus single‑use (SUBs, disposable plastic bags). Traditional SS vessels anchor permanent piping and clean utilities — clean‑in‑place/steam‑in‑place (CIP/SIP), water for injection (WFI, pharmaceutical‑grade water), heating/ventilation/air conditioning (HVAC) — while single‑use systems rely on pre‑sterilized components and simpler support equipment. Thermo Fisher notes single‑use hardware is “significantly less expensive” than stainless alternatives (BioPharm International), and disposables can cut the need for complex automation and plant construction (BioProcess Intl.).

Market analysts estimate that eliminating CIP/SIP and large utility systems can trim project startup by 12–18 months (and associated costs) in a greenfield plant (Mordor Intelligence). AGC Biologics, for example, doubled its Copenhagen campus capacity by adding 8×2,000 L SUBs with only ~$200 million of investment, enabling 150 extra batches per year — an expansion far harder to achieve with a comparably sized stainless facility (AGC Biologics). As utilities scope narrows in single‑use builds, many owners also re‑size water systems; that can include membrane‑based trains such as membrane systems used for industrial water preparation.

Capital and lifecycle cost modeling

The operating expense picture flips over long production runs. Stainless‑steel systems carry higher fixed capital but lower recurring material cost per batch at high throughput. Single‑use eliminates cleaning chemicals and sterilization cycles but adds per‑batch consumable bills (bags, filters, tubing). In practice, one study found that producing 100 kg/year of an antibody in either a 3,000 L stainless plant or a 2,000 L single‑use plant ultimately favored stainless steel after accounting for all SUB consumables (BioProcess Intl.).

Analysts also note that SUB consumable bills can exceed SS OPEX once annual demand rises past roughly 20,000 L of batches (Mordor Intelligence). Bottom line: single‑use wins on initial capital and flexibility (lower CAPEX, faster build), but stainless may win on long‑term cost at very high throughput. Biopharma experts advise detailed life‑cycle cost modeling for each process; for greenfield builds with uncertain volume or multi‑product campaigns, single‑use often yields faster ROI (BioProcess Intl.; BioPharm International), whereas for a known blockbuster (steady, large demand), stainless amortizes its higher CAPEX over more years.

Right‑sizing clean utilities also spans USP water and pretreatment design. It’s common to evaluate upstream filtration steps such as ultrafiltration as part of pretreatment strategies, and polishing options like EDI (electrodeionization) for ultra‑pure water service.

Flexibility, changeovers, and scale limits

Single‑use excels at product flexibility. Removing one campaign means discarding used bags — the “cavities” of single‑use reactors require no cleaning validation because “the bags are discarded after each run” — and studies report up to 70% reduction in start‑up/validation time (BioProcess Intl.). SUBs are portable and standardized; they “can be changed and over scaled quickly and efficiently without lowering plant capacity utilization” and even transferred to new facilities with “minimal or no adaptation” (Pharmaceutical Manufacturer; Pharmaceutical Manufacturer), suiting multi‑product or clinical‑phase programs. An industry survey suggests ~70% of CDMOs (contract development and manufacturing organizations) now offer single‑use options to handle small‑batch and diverse pipelines.

Scale is where stainless still dominates. Large SS fermenters are built up to ~20,000–50,000 L (20–50 m³). Commercial SUBs today max around 2,000–5,000 L for mammalian culture (BioProcess Intl.) — with larger single‑use systems still in development. Microbial fermentation (high oxygen transfer) and very‑large‑volume vaccines generally still use stainless. Producing hundreds of kilograms per year (typical for a blockbuster monoclonal antibody, mAb) often requires a 20,000 L SS fermenter (Access Newswire). Stainless infrastructure also extends to sanitary housings; pharma‑grade lines routinely specify 316L components such as stainless steel cartridge housings.

Facility footprint, utilities, and wastewater

A single‑use‑based plant can have a much smaller footprint. Without permanent piping trains and CIP/SIP, these facilities need fewer clean utilities, smaller cleanrooms, and shorter engineering schedules (BioProcess Intl.; Mordor Intelligence). Analysts flag Asia‑Pacific as the fastest‑growing SU market (≈15.7% CAGR) as emerging CDMOs favor modular plants (Mordor Intelligence). Global trends show CDMOs and hybrid manufacturers installing SUB trains for flexibility while retaining stainless lines for large‑volume runs (Pharmaceutical Manufacturer).

Utilities planning still covers pretreatment and polishing steps: some facilities deploy ultraviolet disinfection as part of utility water strategies, and options like ultraviolet systems are common in low‑chemical approaches. Water rooms often incorporate pre‑RO filtration; technologies such as cartridge filters are standard polishing steps in many designs.

Without CIP cycles, single‑use plants consume far less WFI, steam, and cleaning chemicals; they also remove the need for large wastewater neutralization systems (used to treat CIP effluent) and cut cleanroom air‑change requirements, shrinking HVAC costs (BioProcess Intl.). Facilities that do handle process effluent still plan primary treatment trains; that can include front‑end equipment for solids capture such as physical separation systems. For packaged build‑outs, owners often specify wastewater ancillaries when sizing drain and neutralization capacity.

Cleaning validation and supplier oversight

Eliminating CIP/SIP is a top benefit of single‑use. Pre‑sterilized bags and sensors arrive ready for use; “the bags are discarded after each run,” and manufacturers see roughly 70% faster qualification of SU lines because many equipment‑qualification steps are trivial or omitted (BioProcess Intl.). In SS facilities, CIP skids and chemical dosing remain central; chemical metering gear such as a dosing pump is standard in cleaning cycles.

Single‑use shifts validation rather than eliminating it. Instead of validating cleaning procedures, manufacturers must validate the single‑use products and their suppliers. Regulators (FDA, EMA, etc.) require detailed extractables and leachables (E&L) dossiers for all single‑use components, and upcoming ICH guidance (e.g., new chapter <665>) will make SU E&L testing more stringent (Mordor Intelligence). That means investing in vendor quality, incoming inspections, and material‑compatibility studies. Conversely, SS systems require robust cleaning‑validation protocols; each product change may need swab testing or rinse sampling to prove no carryover. In short, single‑use reduces cleaning‑validation tasks (BioProcess Intl.) but introduces additional E&L validation tasks (Mordor Intelligence).

Market adoption and real‑world data

Adoption is accelerating. The single‑use bioreactor market is projected to grow from about $4.7 billion in 2025 to $8.3 billion by 2030 (≈15% CAGR) (Mordor Intelligence). Single‑use systems already dominate new‑build plants for flexible manufacturing, especially in North America (≈41% market share in 2024) and quickly in Asia. In contrast, almost all very‑large production suites today remain stainless steel: 92% of installed bioreactor capacity above 10,000 L is SS (Pharmaceutical Manufacturer).

The financial impact is visible in case studies. AGC Biologics reports that adding 8×2,000 L SUBs allowed 150 more batches per year on the same campus (roughly doubling output) (AGC Biologics). Rentschler Biopharma’s all‑disposable mammalian facility documented a 40% reduction in fixed plant costs and a 20% increase in annual throughput versus a comparable SS plant, driven by faster changeovers and less downtime (Mordor Intelligence). Thermo Fisher adds that SU facilities have lower sunk cost per campaign, improving speed‑to‑market even for clinical stages (BioPharm International; Mordor Intelligence).

No single technology fits all. Experts emphasize hybrid designs: build SS capacity for any “blockbuster” (steady high demand of hundreds of kg/year) but deploy SUB trains for smaller‑volume, multi‑product lines (Access Newswire; Pharmaceutical Manufacturer). Analytical models suggest single‑use can cut a plant’s water use and validation time drastically (BioProcess Intl.; BioProcess Intl.), while stainless can still deliver unmatched economy for pure, long‑term scale.

What to build next: practical takeaways

Match technology to pipeline. If the portfolio involves multiple products or uncertain demand, single‑use offers lower capital risk, faster deployment, and easy changeover — backed by data showing 12–18 months faster startup (Mordor Intelligence) and 70% less validation time (BioProcess Intl.). Conversely, if building around a single high‑volume product (e.g., a mature biosimilar or stable blockbuster with >10,000 L annual throughput), stainless‑steel reactors may prove more cost‑effective over the long run. Often the optimal approach is hybrid: use SS for the few high‑volume lines and SUBs for auxiliary and development runs (Pharmaceutical Manufacturer).

Regardless, robust cost modeling is essential. Incorporate specific data — 150‑batch gains (AGC Biologics), 37% lower consumable cost (BioPharm International), and 40% fixed‑cost savings (Mordor Intelligence) — into financial models. Plan for single‑use supply assurance (multiple vendors for bags/filters) and include extractables testing in timelines. For utility water design, teams commonly evaluate upstream barriers like membrane systems and final disinfection steps such as ultraviolet when sizing clean utility rooms.

The throughline is clear: single‑use bioreactors can greatly reduce cleaning/validation burden and CAPEX, at the expense of higher per‑batch consumables — a trade‑off quantified across recent industry studies (BioProcess Intl.; BioProcess Intl.; BioProcess Intl.; BioPharm International; BioPharm International; Access Newswire; Mordor Intelligence; AGC Biologics; Pharmaceutical Manufacturer). Data‑backed choices — not dogma — are driving the next generation of biologics manufacturing.